1. Home
  2. HLIT vs MLYS Comparison

HLIT vs MLYS Comparison

Compare HLIT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HLIT
  • MLYS
  • Stock Information
  • Founded
  • HLIT 1988
  • MLYS 2019
  • Country
  • HLIT United States
  • MLYS United States
  • Employees
  • HLIT N/A
  • MLYS N/A
  • Industry
  • HLIT Radio And Television Broadcasting And Communications Equipment
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • HLIT Technology
  • MLYS Health Care
  • Exchange
  • HLIT Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • HLIT 1.0B
  • MLYS 890.6M
  • IPO Year
  • HLIT 1995
  • MLYS 2023
  • Fundamental
  • Price
  • HLIT $10.12
  • MLYS $37.16
  • Analyst Decision
  • HLIT Buy
  • MLYS Strong Buy
  • Analyst Count
  • HLIT 6
  • MLYS 6
  • Target Price
  • HLIT $11.50
  • MLYS $42.60
  • AVG Volume (30 Days)
  • HLIT 1.0M
  • MLYS 2.6M
  • Earning Date
  • HLIT 10-27-2025
  • MLYS 11-10-2025
  • Dividend Yield
  • HLIT N/A
  • MLYS N/A
  • EPS Growth
  • HLIT 16.91
  • MLYS N/A
  • EPS
  • HLIT 0.58
  • MLYS N/A
  • Revenue
  • HLIT $689,084,000.00
  • MLYS N/A
  • Revenue This Year
  • HLIT N/A
  • MLYS N/A
  • Revenue Next Year
  • HLIT $25.21
  • MLYS N/A
  • P/E Ratio
  • HLIT $17.00
  • MLYS N/A
  • Revenue Growth
  • HLIT 24.14
  • MLYS N/A
  • 52 Week Low
  • HLIT $7.80
  • MLYS $8.24
  • 52 Week High
  • HLIT $15.46
  • MLYS $39.20
  • Technical
  • Relative Strength Index (RSI)
  • HLIT 66.72
  • MLYS 86.84
  • Support Level
  • HLIT $9.78
  • MLYS $35.00
  • Resistance Level
  • HLIT $10.13
  • MLYS $15.79
  • Average True Range (ATR)
  • HLIT 0.26
  • MLYS 2.50
  • MACD
  • HLIT 0.06
  • MLYS 2.05
  • Stochastic Oscillator
  • HLIT 94.78
  • MLYS 91.73

About HLIT Harmonic Inc.

Harmonic Inc engaged in broadband access solutions that enable broadband operators to more efficiently and effectively deploy high-speed internet for data, voice, and video services for their customers and versatile and high-performance video delivery software, products, system solutions and services that enable its customers to efficiently create, prepare, store, playout and deliver a full range of high-quality broadcast and streaming video services to consumer devices, including televisions, personal computers, laptops, tablets, and smartphones. It has two segments, Broadband which provides broadband access solutions and related services, and Others; and Video business provides video processing and production and playout solutions and services, and Others.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: